Patents Examined by Hong Sang
  • Patent number: 10808043
    Abstract: The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 20, 2020
    Assignee: Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
    Inventors: Ting Xu, Tao Xu, Xiaoxiao Wang, Qian Li, Minjie Pang, Huimin Zhang, Li Han, Qingqing Zhang
  • Patent number: 10802027
    Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 13, 2020
    Assignee: Biodesix, Inc.
    Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
  • Patent number: 10800852
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: August 4, 2018
    Date of Patent: October 13, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray
  • Patent number: 10799570
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: October 13, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10792349
    Abstract: Compositions for the treatment of cancer include an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cell vaccine and an anti-galectin-3 antibody. Increased titers of anti-galectin-3 antibodies were correlated with clinical outcome.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 6, 2020
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
  • Patent number: 10787506
    Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 29, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventor: Patricia Forgez
  • Patent number: 10775383
    Abstract: Provided herein are PD-L1 antibodies and methods for using the same for detecting human PD-L1 protein in biological samples. The PD-L1 antibodies and methods may be useful for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition, among other uses.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 15, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
  • Patent number: 10775382
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: September 15, 2020
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Patent number: 10772976
    Abstract: Disclosed is a monoclonal antibody reactive with a glycopeptide shown in (a), and not reactive with a glycopeptide shown in (b)
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 15, 2020
    Assignee: SYSMEX CORPORATION
    Inventors: Yukiko Higa, Masatoshi Suganuma, Yuriko Egashira
  • Patent number: 10766961
    Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: September 8, 2020
    Assignee: ImClone LLC
    Inventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
  • Patent number: 10759850
    Abstract: The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 1, 2020
    Assignee: Berg LLC
    Inventors: Wenfang Sybil Wu, Shobha Ravipaty, Tracey Friss, Viatcheslav R. Akmaev, Nikunj Narendra Tanna
  • Patent number: 10752683
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Patent number: 10753935
    Abstract: The invention generally relates to diagnostic, prognostic, and monitoring methods and assays for breast cancer and kits that may be used in such methods. More particularly, the invention relates to a method of prognosis of a patient afflicted with breast cancer, including determining the level of HER2/CB2 heteromer expression in a biological sample obtained from the patient.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: August 25, 2020
    Assignee: Zelda Therapeutics Operations Pty Ltd.
    Inventors: Cristina Sánchez Garcia, Sandra Blasco Benito, Eduardo Pérez Gómez
  • Patent number: 10745486
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 18, 2020
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Patent number: 10745479
    Abstract: This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: August 18, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Shou-Ching S. Jaminet, Harold F. Dvorak
  • Patent number: 10738129
    Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: August 11, 2020
    Assignee: Health Research, Inc.
    Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
  • Patent number: 10730922
    Abstract: The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 4, 2020
    Assignee: Miltenyi Biotech B.V. & Co. KG
    Inventors: Stefan Dübel, Sarah-Jane Kellmann, Holger Thie
  • Patent number: 10730951
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, Kevin Walsh, Patricia De Almeida, James Andya, Ye Shen
  • Patent number: 10722565
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: July 28, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10716851
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: July 21, 2020
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak